-
1دورية أكاديمية
المؤلفون: Michael, M., Groothoff, J. W., Shasha-Lavsky, H., Lieske, J. C., Frishberg, Y., Simkova, E., Sellier-Leclerc, A. L., Devresse, A., Guebre-Egziabher, F., Bakkaloglu, S. A., Mourani, C., Saqan, R., Singer, R., Willey, R., Habtemariam, B., Gansner, J. M., Bhan, I., Mcgregor, T., Magen, D.
المساهمون: Texas Children's Hospital Houston, USA, Baylor College of Medicine (BCM), Baylor University, Emma Children’s Hospital, Amsterdam UMC - Amsterdam University Medical Center, Galilee Medical Center Nahariya, Israel, Bar-Ilan University Israël, Mayo Clinic Rochester, Shaare Zedek Medical Center Jerusalem, Israel, Al Jalila Children's Specialty Hospital, Filières Maladies Rares ORKID et ERK-Net, Centre d'Investigation Clinique Bron (CIC1407), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupement Hospitalier Est Bron, Cliniques Universitaires Saint-Luc Bruxelles, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Gazi University, Hôpital Hôtel Dieu de France Beirut, Lebanon (2HDF), Jordan University of Science and Technology Irbid, Jordan (JUST), Canberra Health Services Garran, ACT, Australia (CHS), Alnylam Pharmaceuticals Cambridge, MA, USA, Rambam Health Care Campus Haifa, Israel
المصدر: ISSN: 0272-6386.
مصطلحات موضوعية: Lumasiran, RNA interference (RNAi), adverse events, anti-drug antibodies, cardiac dysfunction, efficacy, glycolate, hemodialysis, kidney disease, nephrocalcinosis, pediatric, pharmacodynamics, pharmacokinetics, phase 3 clinical trial, plasma oxalate (POx), primary hyperoxaluria type 1 (PH1), safety, systemic oxalosis, urinary oxalate (UOx), [SDV]Life Sciences [q-bio]
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35843439; inserm-03831070; https://www.hal.inserm.fr/inserm-03831070Test; https://www.hal.inserm.fr/inserm-03831070/documentTest; https://www.hal.inserm.fr/inserm-03831070/file/1-s2.0-S0272638622007715-main.pdfTest; PUBMED: 35843439
الإتاحة: https://doi.org/10.1053Test/j.ajkd.2022.05.012
https://www.hal.inserm.fr/inserm-03831070Test
https://www.hal.inserm.fr/inserm-03831070/documentTest
https://www.hal.inserm.fr/inserm-03831070/file/1-s2.0-S0272638622007715-main.pdfTest -
2دورية أكاديمية
المؤلفون: Michael, M., Groothoff, J. W., Shasha-Lavsky, H., Lieske, J. C., Frishberg, Y., Simkova, E., Sellier-Leclerc, A. L., Devresse, A., Guebre-Egziabher, F., Bakkaloglu, S. A., Mourani, C., Saqan, R., Singer, R., Willey, R., Habtemariam, B., Gansner, J. M., Bhan, I., Mcgregor, T., Magen, D.
المساهمون: Texas Children's Hospital Houston, USA, Baylor College of Medicine (BCM), Baylor University, Emma Children’s Hospital, Amsterdam UMC - Amsterdam University Medical Center, Galilee Medical Center Nahariya, Israel, Bar-Ilan University Israël, Mayo Clinic Rochester, Shaare Zedek Medical Center Jerusalem, Israel, Al Jalila Children's Specialty Hospital, Filières Maladies Rares ORKID et ERK-Net, Centre d'Investigation Clinique Bron (CIC1407), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupement Hospitalier Est Bron, Cliniques Universitaires Saint-Luc Bruxelles, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Gazi University, Hôpital Hôtel Dieu de France Beirut, Lebanon (2HDF), Jordan University of Science and Technology Irbid, Jordan (JUST), Canberra Health Services Garran, ACT, Australia (CHS), Alnylam Pharmaceuticals Cambridge, MA, USA, Rambam Health Care Campus Haifa, Israel
المصدر: ISSN: 0272-6386.
مصطلحات موضوعية: Lumasiran, RNA interference (RNAi), adverse events, anti-drug antibodies, cardiac dysfunction, efficacy, glycolate, hemodialysis, kidney disease, nephrocalcinosis, pediatric, pharmacodynamics, pharmacokinetics, phase 3 clinical trial, plasma oxalate (POx), primary hyperoxaluria type 1 (PH1), safety, systemic oxalosis, urinary oxalate (UOx), [SDV]Life Sciences [q-bio]
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35843439; inserm-03831070; https://www.hal.inserm.fr/inserm-03831070Test; https://www.hal.inserm.fr/inserm-03831070/documentTest; https://www.hal.inserm.fr/inserm-03831070/file/1-s2.0-S0272638622007715-main.pdfTest; PUBMED: 35843439
الإتاحة: https://doi.org/10.1053Test/j.ajkd.2022.05.012
https://www.hal.inserm.fr/inserm-03831070Test
https://www.hal.inserm.fr/inserm-03831070/documentTest
https://www.hal.inserm.fr/inserm-03831070/file/1-s2.0-S0272638622007715-main.pdfTest -
3دورية أكاديمية
المؤلفون: Michael, M., Groothoff, J. W., Shasha-Lavsky, H., Lieske, J. C., Frishberg, Y., Simkova, E., Sellier-Leclerc, A. L., Devresse, A., Guebre-Egziabher, F., Bakkaloglu, S. A., Mourani, C., Saqan, R., Singer, R., Willey, R., Habtemariam, B., Gansner, J. M., Bhan, I., Mcgregor, T., Magen, D.
المساهمون: Texas Children's Hospital Houston, USA, Baylor College of Medicine (BCM), Baylor University, Emma Children’s Hospital, Amsterdam UMC - Amsterdam University Medical Center, Galilee Medical Center Nahariya, Israel, Bar-Ilan University Israël, Mayo Clinic Rochester, Shaare Zedek Medical Center Jerusalem, Israel, Al Jalila Children's Specialty Hospital, Filières Maladies Rares ORKID et ERK-Net, Centre d'Investigation Clinique Bron (CIC1407), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupement Hospitalier Est Bron, Cliniques Universitaires Saint-Luc Bruxelles, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Gazi University, Hôpital Hôtel Dieu de France Beirut, Lebanon (2HDF), Jordan University of Science and Technology Irbid, Jordan (JUST), Canberra Health Services Garran, ACT, Australia (CHS), Alnylam Pharmaceuticals Cambridge, MA, USA, Rambam Health Care Campus Haifa, Israel
المصدر: ISSN: 0272-6386.
مصطلحات موضوعية: Lumasiran, RNA interference (RNAi), adverse events, anti-drug antibodies, cardiac dysfunction, efficacy, glycolate, hemodialysis, kidney disease, nephrocalcinosis, pediatric, pharmacodynamics, pharmacokinetics, phase 3 clinical trial, plasma oxalate (POx), primary hyperoxaluria type 1 (PH1), safety, systemic oxalosis, urinary oxalate (UOx), [SDV]Life Sciences [q-bio]
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35843439; inserm-03831070; https://inserm.hal.science/inserm-03831070Test; https://inserm.hal.science/inserm-03831070/documentTest; https://inserm.hal.science/inserm-03831070/file/1-s2.0-S0272638622007715-main.pdfTest; PUBMED: 35843439
الإتاحة: https://doi.org/10.1053Test/j.ajkd.2022.05.012
https://inserm.hal.science/inserm-03831070Test
https://inserm.hal.science/inserm-03831070/documentTest
https://inserm.hal.science/inserm-03831070/file/1-s2.0-S0272638622007715-main.pdfTest -
4دورية أكاديمية
المؤلفون: Michael, M., Groothoff, J. W., Shasha-Lavsky, H., Lieske, J. C., Frishberg, Y., Simkova, E., Sellier-Leclerc, A. L., Devresse, A., Guebre-Egziabher, F., Bakkaloglu, S. A., Mourani, C., Saqan, R., Singer, R., Willey, R., Habtemariam, B., Gansner, J. M., Bhan, I., Mcgregor, T., Magen, D.
المساهمون: Texas Children's Hospital Houston, USA, Baylor College of Medicine (BCM), Baylor University, Emma Children’s Hospital, Amsterdam UMC - Amsterdam University Medical Center, Galilee Medical Center Nahariya, Israel, Bar-Ilan University Israël, Mayo Clinic Rochester, Shaare Zedek Medical Center Jerusalem, Israel, Al Jalila Children's Specialty Hospital, Filières Maladies Rares ORKID et ERK-Net, Centre d'Investigation Clinique Bron (CIC1407), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupement Hospitalier Est Bron, Cliniques Universitaires Saint-Luc Bruxelles, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Gazi University, Hôpital Hôtel Dieu de France Beirut, Lebanon (2HDF), Jordan University of Science and Technology Irbid, Jordan (JUST), Canberra Health Services Garran, ACT, Australia (CHS), Alnylam Pharmaceuticals Cambridge, MA, USA, Rambam Health Care Campus Haifa, Israel
المصدر: ISSN: 0272-6386.
مصطلحات موضوعية: Lumasiran, RNA interference (RNAi), adverse events, anti-drug antibodies, cardiac dysfunction, efficacy, glycolate, hemodialysis, kidney disease, nephrocalcinosis, pediatric, pharmacodynamics, pharmacokinetics, phase 3 clinical trial, plasma oxalate (POx), primary hyperoxaluria type 1 (PH1), safety, systemic oxalosis, urinary oxalate (UOx), [SDV]Life Sciences [q-bio]
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35843439; inserm-03831070; https://inserm.hal.science/inserm-03831070Test; https://inserm.hal.science/inserm-03831070/documentTest; https://inserm.hal.science/inserm-03831070/file/1-s2.0-S0272638622007715-main.pdfTest; PUBMED: 35843439
الإتاحة: https://doi.org/10.1053Test/j.ajkd.2022.05.012
https://inserm.hal.science/inserm-03831070Test
https://inserm.hal.science/inserm-03831070/documentTest
https://inserm.hal.science/inserm-03831070/file/1-s2.0-S0272638622007715-main.pdfTest -
5دورية أكاديمية
المؤلفون: Michael, M., Groothoff, J. W., Shasha-Lavsky, H., Lieske, J. C., Frishberg, Y., Simkova, E., Sellier-Leclerc, A. L., Devresse, A., Guebre-Egziabher, F., Bakkaloglu, S. A., Mourani, C., Saqan, R., Singer, R., Willey, R., Habtemariam, B., Gansner, J. M., Bhan, I., Mcgregor, T., Magen, D.
المساهمون: Texas Children's Hospital Houston, USA, Baylor College of Medicine (BCM), Baylor University, Emma Children’s Hospital, Amsterdam UMC - Amsterdam University Medical Center, Galilee Medical Center Nahariya, Israel, Bar-Ilan University Israël, Mayo Clinic Rochester, Shaare Zedek Medical Center Jerusalem, Israel, Al Jalila Children's Specialty Hospital, Filières Maladies Rares ORKID et ERK-Net, Centre d'Investigation Clinique Bron (CIC1407), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupement Hospitalier Est Bron, Cliniques Universitaires Saint-Luc Bruxelles, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Gazi University, Hôpital Hôtel Dieu de France Beirut, Lebanon (2HDF), Jordan University of Science and Technology Irbid, Jordan (JUST), Canberra Health Services Garran, ACT, Australia (CHS), Alnylam Pharmaceuticals Cambridge, MA, USA, Rambam Health Care Campus Haifa, Israel
المصدر: ISSN: 0272-6386.
مصطلحات موضوعية: Lumasiran, RNA interference (RNAi), adverse events, anti-drug antibodies, cardiac dysfunction, efficacy, glycolate, hemodialysis, kidney disease, nephrocalcinosis, pediatric, pharmacodynamics, pharmacokinetics, phase 3 clinical trial, plasma oxalate (POx), primary hyperoxaluria type 1 (PH1), safety, systemic oxalosis, urinary oxalate (UOx), [SDV]Life Sciences [q-bio]
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35843439; inserm-03831070; https://www.hal.inserm.fr/inserm-03831070Test; https://www.hal.inserm.fr/inserm-03831070/documentTest; https://www.hal.inserm.fr/inserm-03831070/file/1-s2.0-S0272638622007715-main.pdfTest; PUBMED: 35843439
الإتاحة: https://doi.org/10.1053Test/j.ajkd.2022.05.012
https://www.hal.inserm.fr/inserm-03831070Test
https://www.hal.inserm.fr/inserm-03831070/documentTest
https://www.hal.inserm.fr/inserm-03831070/file/1-s2.0-S0272638622007715-main.pdfTest -
6دورية أكاديمية
المؤلفون: Michael, M., Groothoff, J. W., Shasha-Lavsky, H., Lieske, J. C., Frishberg, Y., Simkova, E., Sellier-Leclerc, A. L., Devresse, A., Guebre-Egziabher, F., Bakkaloglu, S. A., Mourani, C., Saqan, R., Singer, R., Willey, R., Habtemariam, B., Gansner, J. M., Bhan, I., Mcgregor, T., Magen, D.
المساهمون: Texas Children's Hospital Houston, USA, Baylor College of Medicine (BCM), Baylor University, Emma Children’s Hospital, Amsterdam UMC - Amsterdam University Medical Center, Galilee Medical Center Nahariya, Israel, Bar-Ilan University Israël, Mayo Clinic Rochester, Shaare Zedek Medical Center Jerusalem, Israel, Al Jalila Children's Specialty Hospital, Filières Maladies Rares ORKID et ERK-Net, Centre d'Investigation Clinique Bron (CIC1407), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupement Hospitalier Est Bron, Cliniques Universitaires Saint-Luc Bruxelles, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Gazi University, Hôpital Hôtel Dieu de France Beirut, Lebanon (2HDF), Jordan University of Science and Technology Irbid, Jordan (JUST), Canberra Health Services Garran, ACT, Australia (CHS), Alnylam Pharmaceuticals Cambridge, MA, USA, Rambam Health Care Campus Haifa, Israel
المصدر: ISSN: 0272-6386.
مصطلحات موضوعية: Lumasiran, RNA interference (RNAi), adverse events, anti-drug antibodies, cardiac dysfunction, efficacy, glycolate, hemodialysis, kidney disease, nephrocalcinosis, pediatric, pharmacodynamics, pharmacokinetics, phase 3 clinical trial, plasma oxalate (POx), primary hyperoxaluria type 1 (PH1), safety, systemic oxalosis, urinary oxalate (UOx), [SDV]Life Sciences [q-bio]
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35843439; inserm-03831070; https://www.hal.inserm.fr/inserm-03831070Test; https://www.hal.inserm.fr/inserm-03831070/documentTest; https://www.hal.inserm.fr/inserm-03831070/file/1-s2.0-S0272638622007715-main.pdfTest; PUBMED: 35843439
الإتاحة: https://doi.org/10.1053Test/j.ajkd.2022.05.012
https://www.hal.inserm.fr/inserm-03831070Test
https://www.hal.inserm.fr/inserm-03831070/documentTest
https://www.hal.inserm.fr/inserm-03831070/file/1-s2.0-S0272638622007715-main.pdfTest